Menu
Search Close

News

Unaudited Interim Results for the six month period to 31st October 2010

31st January 2011

Scancell Holdings plc, the developer of therapeutic cancer and infectious disease vaccines based on its patented Immunobody® platform, is pleased to announce the interim results for the six month period ended 31st October 2010.

Highlights:

  • Successful progression of SCIB1, Scancell's lead vaccine for melanoma, which entered clinical trials in June 2010

  • Raised £2.5 million in April 2010 with new and current shareholders

  • Moved from PLUS to AIM in July 2010

  • Secured licensing agreements with:

    • the National Institutes of Health (an agency of the United States Department of Health and Human Services); and

    • Cancer Research Technology Ltd (Cancer Research UK's commercialisation and development arm)

  • Entered strategic collaborations with:

    • ImmuneRegen BioSciences, Inc.®; and

    • immatics biotechnologies GmbH

Post-period Highlights:

    • Four patients recruited to date for the clinical trials

    • Approval obtained to open a fourth UK patient recruitment site and to expand the patient population in the Phase I part of the study, to include all patients with Stage III and Stage IV malignant melanoma

    • Escalation of the dose and recruitment of the next group of patients in SCIB1 trial approved by the Cohort Review Committee

 

For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant
+ 44 (0)207 245 1100

Hansard Communications
Kirsty Corcoran/Adam Reynolds
+44 (0)207 245 1100

Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

Matrix Corporate Capital LLP - Joint Broker
Robert Naylor/Stephen Waterman

View the full results 

Webcasts, Interviews and Media Coverage

Scancell to begin dosing in UK phase II trial of flagship skin cancer drug

Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.

Thu, 25 Apr 2019 10:56:00

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

Thu, 25 Apr 2019 12:20:00

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00